NorthWest Biotherapeutics Inc (NWBO)

[TiltMyBrain]

Only truly malevolent characters could hope for a negative outcome. I think that when the data is unblinded that we will see a very meaningful survival tail for DCVax-L. In any event we will know without question how many of the 232 patients initially treated with DCVax-L remained alive at four years as well as the 66 patients who were treated with SOC initially and then crossed over to DCVax-L and the 33 patients treated only with SOC. This survival tail data is enormously more important than median progression free survival and median overall survival. The decision of management to let the trial continue longer before unblinding means that we should have a clear understanding of the survival tail of DCVax-L.

Larry Smith